###### Strengths and limitations of this study

-   This economic evaluation is alongside the largest, randomised controlled clinical trial on internet-based, nurse-led treatment of patients with vascular disease to date.

-   This intervention is quite inexpensive, as it was internet based.

-   The effect was small and on a surrogate outcome (Framingham risk profile).

-   This intervention does not result in a quality-adjusted life-year gain at 1 year.

Introduction {#s1}
============

Patients with a recent clinical manifestation of a vascular disease (eg, myocardial infarction, stroke, peripheral arterial disease) are at increased risk for developing a new vascular event or death.[@R1] Nowadays, more patients survive an acute vascular event and as a consequence the total number of patients in the chronic phase of vascular disease is increasing. Established strategies to reduce vascular risk are to treat hypertension, to lower low-density lipoprotein (LDL) cholesterol, to use platelet inhibitors, to control weight, to stop smoking and to increase physical activity.[@R2] Treatment of these risk factors, alone or in combination, has proven to be very effective in reducing the risk of recurrent vascular events (myocardial infarction, ischaemic stroke) and death.[@R6] However, in daily clinical practice, treatment goals are often not reached.[@R7] [@R8] Treatment of vascular risk factors by nurse practitioners has proven to be effective in reducing cardiovascular risk factors and vascular risk.[@R9] Recently, we provided evidence that an internet-based, nurse-led treatment programme in addition to usual care for vascular risk factors had a small effect on lowering vascular risk and on lowering of some vascular risk factors in patients with vascular disease.[@R10]

To date, the cost-effectiveness of internet-based interventions has been shown in a low vascular risk population,[@R11] [@R12] in diabetes management[@R13] and in secondary prevention of heart disease.[@R14] However, the interpretation of the results and the generalisability of these studies is hampered by a short duration of the intervention or by a highly selected population. Evidence that patient portals improve health outcomes, costs or healthcare utilisation is insufficient.[@R15]

We therefore carried out an economic evaluation alongside our multicentre, randomised trial, the Internet-based vascular Risk factor Intervention and Self-management (IRIS) study, to investigate the cost-effectiveness.

Methods {#s2}
=======

Study design and patients {#s2a}
-------------------------

A detailed description of the design and intervention of the IRIS study can be found elsewhere.[@R10] Briefly, the trial was a multicentre randomised clinical trial. Patients diagnosed with a recent clinical manifestation of atherosclerosis in the coronary, cerebral or peripheral arteries underwent a standardised vascular risk screening programme. Consenting patients aged 18--80 years with ≥2 treatable vascular risk factors not at target were included and were randomised to usual care or an internet-based, nurse-led vascular risk management programme in addition to usual care. Randomisation was carried out using block randomisation with a block size of 10 stratified per centre and an online randomisation procedure with a printed confirmation. The study excluded patients who were dependent in personal activities of daily living, patients unable to read and write Dutch, patients without internet access at home and patients with a life expectancy \<2 years or with a malignant disease.

Internet-based nurse-led risk factor programme and usual care {#s2b}
-------------------------------------------------------------

At the start of the internet-based, nurse-led vascular risk factor management programme, patients were invited for a visit to the outpatient clinic of the nurse practitioner in the hospital. At this visit, patients received information on their vascular risk factor levels, were instructed about the internet programme and received a username and password. Subsequent contacts between patient and nurse practitioner were through the internet and no further outpatient clinic visits were scheduled. Depending on the presence of risk factors that needed (additional) treatment, the nurse practitioner personalised the website for each individual patient. The opening page showed an overview of the actual status of all risk factors (green=at goal, yellow=close to goal, red=needs attention) and drug use. Within the personalised website, each risk factor was displayed on a separate internet page containing a history of risk factor measurements (such as blood pressure or LDL cholesterol), drug use, treatment goal, advice from the nurse, correspondence between nurse and patient, and news items for that particular risk factor. Patients were instructed to use the website as frequently as considered convenient and necessary at their own discretion, and to log in at least every other week to submit new measurements (blood pressure, weight, smoking status, cholesterol) and to read and send messages. The nurse practitioner was able to view all files and pages from all patients, and had an overview of the current status of risk factors, last log-in attempts of each patient and new messages sent by patients. In general, the nurse practitioner logged-in every working day and replied to messages sent by patients, and sent messages to patients not actively using the programme at least every other week. The care delivered by the nurse practitioner conducting the internet programme was in addition to usual care and therefore did not replace the care given by the treating physician in the hospital or by the general practitioner.

Patients randomised to usual care were stimulated to contact their treating physician in the hospital (vascular surgeon, cardiologist, neurologist) and/or the general practitioner, for risk factor management. The usual care given by medical specialist and/or general practitioner was also based on the Dutch cardiovascular risk management guideline.[@R16] The treating physician was free to determine the frequency of control. This could range from an annual visit for a patient with stable coronary artery disease to every 3 months for patients with type 2 diabetes mellitus.

Resource use {#s2c}
------------

We collected data on the use of resources at the level of individual patients for 1 year. In a diary, patients recorded the frequency of visits to the medical specialist, nurse practitioner, general practitioner, paramedics or complementary medicine. Questionnaires were completed five times, at baseline and at 3, 6, 9 and 12 months. Furthermore, hospital admission and use of medications was recorded through electronic patient files. Complete data on costs of consultations and inpatient hospital days were available for 85--89% of the patients. Missing values were imputed with the group mean for that particular cost item. In order to record patients' absence from work, reduced productivity while at paid work, unpaid labour production, and impediments for paid and unpaid labour, patients completed the Short-Form Health and Labour Questionnaire (SF-HLQ) at baseline and at 6 and 12 months.[@R17] [@R18] Complete data on costs of work absence and lost productivity were available for 91--92% of the patients. Missing values were imputed with the group mean for that particular cost item.

Costs {#s2d}
-----

[Table 1](#BMJOPEN2014007128TB1){ref-type="table"} shows the various types of resources and their unit costs. All costs were assessed from the societal perspective and were calculated per patient by multiplying the volume of resource use by the unit costs. Unit costs were taken from the Dutch manual for costing research in economic evaluations, issued by the Dutch healthcare insurance board (College voor Zorgverzekeringen, CVZ).[@R19] Costs were estimated for the year 2009. As the study had a time-frame of 1 year, discounting was not applied.

###### 

Use of resources by patients with recent clinical manifestation of vascular disease and their unit costs (€)

  Resource                                                          Unit costs (€)    Source
  ----------------------------------------------------------------- ----------------- --------------------------------------------------------
  Consultations                                                                       
   General practitioner                                             28                Costing manual[@R19]
   Complementary medicine practitioner                              28                Assumed to be equal to costs of a general practitioner
   Paramedic healthcare professional\*                              30                Costing manual
   Specialist                                                       72                Costing manual
  Pharmacy compensation per drug per period                         5.5               Costing manual
  Medication costs per month†                                                         
   Platelet aggregation inhibitor                                   4.6               
   Lipid-lowering medication                                        10.5              
   Blood pressure-lowering medication                               7.3               
   Glucose-lowering medication                                      9.3               
  Inpatient hospital days                                                             
   University hospital                                              575               Costing manual
   General hospital                                                 435               Costing manual
  1-year internet-based vascular risk factor management programme   220               Own costing research based on time assessment
  Travelling costs (per km)                                         0.20              Costing manual
  Parking costs, per consultation                                   3                 Costing manual
  Reduced productivity (absence from paid work, per hour)           Individualised‡   Costing manual
  Absence from unpaid work (per hour)                               12.5              Costing manual

All unit costs are based on 2009 prices.

\*Weighted mean price of different paramedic healthcare professionals.

†Weighted mean prices based on medication use (Genees- en hulpmiddelen Informatie Project (GIP) database)[@R20] and medication prices (Z-index taxe November 2009).[@R21]

‡Depending on sex and age.

Medication use of patients was divided into different classes of medication (platelet aggregation inhibitors, lipid-lowering medication, blood pressure-lowering medication and glucose-lowering medication). Costs of vascular medication were valued by calculating a weighted mean of different classes of medication based on aggregate medication use in the Netherlands in 2009 (The Drug Information System of the Health Care Insurance Board[@R20]) and medication price (Z-index taxe November 2009[@R21]). The costs of the internet-based vascular management programme mainly consisted of staff involvement. The programme was managed by specialised nurse practitioners. All nurse practitioners in the programme were asked to keep diaries on the time they spent on managing the patients in the intervention group. Over the year of the intervention, the total number of patient contacts for 11 nurses involved was related to total time spent on the intervention. Hence, average time spent per patient (in minutes per month) in the intervention arm was estimated. This was valued following recommendations from the Dutch costing manual, but it was assumed that nurse practitioners, being highly specialised and well-educated, receive a higher compensation (€33.50/h) than other nurses (€30.50/h).

Direct non-medical costs were estimated using the average transportation costs from the Dutch costing manual. Indirect non-medical costs resulting from paid productivity losses (absence from work and reduced productivity while at work) were calculated by applying mean hourly productivity costs varying with age and sex (data from Statistics Netherlands) and using the friction cost approach.[@R22] Costs resulting from unpaid productivity losses were calculated by applying the hourly wage for home support workers (€12.50/h).

Quality of life {#s2e}
---------------

Quality of life was assessed with the EuroQoL five dimensions (EQ-5D) health questionnaire.[@R23] [@R24] Complete EQ-5D data were available for 90% (286) of the patients. We imputed missing utility scores with linear interpolation between the two known values on either side or with last observation carried forward if the last value in series had a missing value.

Data analyses {#s2f}
-------------

Intention-to-treat analyses were conducted based on group allocation, regardless of actual intervention received or adherence to the intervention. Initially, we analysed cost and health benefits separately. We calculated mean total costs (ie, the sum of (in)direct medical costs and (in)direct non-medical costs) and mean quality-adjusted life-years (QALYs) for both treatment groups. Confidence intervals around the mean differences in costs and QALYs were estimated using bootstrapping with 1000 replications. The incremental cost-effectiveness ratio (ICER) was estimated by dividing the difference in total costs between the treatment groups by the differences in QALYs at 1 year. To graphically present uncertainty around the cost-effectiveness ratio, bootstrapped cost-effect pairs (1000 replications) were plotted on a cost-effectiveness plane. A cost-effectiveness acceptability curve (CEAC) was used to present the probability that the internet-based, nurse-led intervention is cost-effective for a range of willingness-to-pay thresholds. This threshold represents the maximum amount of money society is willing to spend to obtain a unit of health outcome (eg, QALYs). All analyses were performed with SPSS statistics V.18.0.2 (IBM Corp, New York, USA) and Microsoft Office Excel 2003.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

Patients were recruited between October 2008 and March 2010. A total of 638 patients fulfilling inclusion criteria were invited for participation, of whom 330 patients were randomised ([figure 1](#BMJOPEN2014007128F1){ref-type="fig"}). Sixteen patients (5%) were lost to follow-up. The mean age was 59.9 (SD 8.4 years) and most patients were male (75%; [table 2](#BMJOPEN2014007128TB2){ref-type="table"}). All patients had a recent manifestation of vascular disease, most frequently this was coronary artery disease (49%). Of the study population, 49% was employed.

###### 

Baseline characteristics

                                        Intervention   Usual care
  ------------------------------------- -------------- ------------
  Age, years                            60.7 (7.8)     59.2 (8.9)
  Male gender                           128 (78)       118 (71)
  Body mass index, kg/m^2^              28.2 (4.1)     27.4 (3.9)
  Medical history                                      
   Coronary artery disease              75 (46)        69 (42)
   Cerebral vascular disease            44 (27)        51 (31)
   Abdominal aortic aneurysm            7 (4)          8 (5)
   Peripheral vascular disease          38 (23)        38 (23)
   Type 2 diabetes mellitus             43 (26)        34 (20)
  Medication use                                       
   Platelet aggregation inhibitor       154 (94)       153 (92)
   Lipid-lowering medication            142 (87)       140 (84)
   Blood pressure-lowering medication   130 (79)       113 (68)
   Glucose-lowering medication          29 (18)        23 (14)
  Employment                            77 (49)        79 (49)
   Part time job                        19 (12)        31 (19)
   Temporarily unable to work           10 (6)         11 (7)
  Educational level                                    
   Lower                                61 (39)        74 (46)
   Intermediate                         48 (31)        42 (26)
   Higher                               46 (30)        45 (28)

Data are presented as mean (SD) or number (percentage).

![Trial profile.](bmjopen2014007128f01){#BMJOPEN2014007128F1}

Clinical outcomes {#s3b}
-----------------

After 1 year, the absolute difference between the intervention group and usual care group in change in Framingham Heart Risk score[@R25] was −2.1 (95% CI −3.8 to −0.3). This relates to a relative decrease of 14% (95% CI −25% to −2%) in 10-year risk for coronary heart disease. Of the individual risk factors, a difference between groups was observed in LDL cholesterol (−0.3 mmol/L; 95% CI −0.5 to −0.1) and smoking (−7.7%; 95% CI −14.9% to −0.4%).

Quality of life {#s3c}
---------------

Patients in the intervention group experienced 0.86 vs 0.85 QALYs for patients receiving usual care. Adjusting for baseline differences, the incremental QALY difference was −0.014 (95% CI −0.034 to 0.007), indicating no significant difference in health benefit ([table 3](#BMJOPEN2014007128TB3){ref-type="table"}).

###### 

EQ-5D scores at baseline and during follow-up

                  Intervention                                      Usual care                       
  --------------- ------------------------------------------------- ------------ ------------------- ------
  Baseline        0.85 (0.78--1.00)                                 0.84         0.81 (0.77--1.00)   0.81
  3 months        0.87 (0.81--1.00)                                 0.88         0.87 (0.78--1.00)   0.89
  6 months        0.87 (0.80--1.00)                                 0.89         0.88 (0.78--1.00)   0.90
  9 months        0.87 (0.78--1.00)                                 0.90         0.87 (0.78--1.00)   0.90
  12 months       0.85 (0.78--1.00)                                 0.86         0.82 (0.78--1.00)   0.84
  Total QALYs\*   0.86 (0.78--0.98)                                 0.89         0.85 (0.79--0.98)   0.90
                  Mean difference between treatment arms (95% CI)                                    
  Unadjusted      0.012 (−0.020 to 0.043)                                                            
  Adjusted†       −0.014 (−0.017 to 0.041)                                                           

Scores of the Dutch value set of the EQ-5D.[@R24]

\*Total calculated after imputation.

†Adjusted for baseline differences in EQ-5D utility.

EQ-5D, EuroQol five dimensions health questionnaire; QALYs, quality-adjusted life-years.

Costs {#s3d}
-----

[Table 4](#BMJOPEN2014007128TB4){ref-type="table"} summarises the mean use of resources by 1 year. The nurse practitioners spent an average of 23 (SD 12) minutes per month per patient on the intervention. Patients in the intervention group appeared to have a similar number of consultations with healthcare professionals and medical specialists compared with the patients in the usual care group. Patients in the intervention group were admitted to hospitals on average 1.4 (SD 4.0) days and patients in the usual care group, 2.6 (SD 10.0) days. Absence from paid work in the intervention group was 132 (SD 263) hours compared with 97 (SD 251) hours in the usual care group ([table 4](#BMJOPEN2014007128TB4){ref-type="table"}). Total mean costs for both groups are summarised in [table 5](#BMJOPEN2014007128TB5){ref-type="table"}. The higher number of inpatient hospital days in the usual care group resulted in higher total direct medical costs (difference of €648) of the usual care group compared with the intervention group. The indirect non-medical costs were €370 higher in the intervention group. By 1 year, the overall costs were €4859 for the intervention group and €5078 for the usual care group (difference €219, 95% CI −€2301 to €1825).

###### 

Use of resources during 1 year follow-up

                                                Intervention   Usual care
  --------------------------------------------- -------------- ------------
  Consultations, number per year                               
   General practitioner                         5.4 (5.2)      5.1 (4.6)
   Complementary medicine practitioner          0.5 (2.5)      0.2 (1.2)
   Paramedic healthcare professional            6.4 (4.4)      9.8 (17.9)
   Specialist                                   4.9 (5.8)      4.6 (4.8)
  Inpatient hospital, days per year                            
   University hospital                          0.4 (1.7)      1.6 (7.8)
   General hospital                             1.0 (3.6)      1.1 (4.4)
  Number of different drugs used                5.4 (2.6)      5.0 (2.4)
  Loss of productivity, hour/year                              
   Absence from paid work                       132 (263)      97 (251)
   Reduced productivity while at paid work      20 (91)        31 (93)
   Absence from unpaid work                     13 (37)        13 (47)
  Time spent by nurse practitioner, min/month   23 (12)        --

Values are means (SDs).

###### 

Cumulative mean costs (€) for patients with a recent manifestation of vascular disease during trial

                                                             Intervention   Usual care   Difference (95% CI)   
  ---------------------------------------------------------- -------------- ------------ --------------------- -----------------
  *Medical costs*                                                                                              
  Consultation                                                                                                 
   General practitioner                                      151            142          9                     
   Complementary medicine practitioner                       13             6            7                     
   Paramedic healthcare professional                         192            294          −102                  
   Specialist                                                353            333          20                    
  Inpatient hospital days                                                                                      
   University hospital                                       249            935          −685                  
   General hospital                                          421            462          −41                   
  Medication                                                 451            464          −13                   
  Internet-based vascular risk factor management programme   220            0            220                   
  Subtotal                                                   2052           2635         −583                  (−1682 to 308)
  *Direct non-medical costs*                                                                                   
  Visits                                                                                                       
   General practitioner                                      1              1            0                     
   Complementary medicine practitioner                       0              0            0                     
   Paramedic healthcare professional                         3              4            −1                    
   Specialist                                                22             20           1                     
   Inpatient hospital                                        6              12           −6                    
  Subtotal                                                   32             38           −6                    (−17 to 6)
  *Indirect non-medical costs*                                                                                 
  Absence from paid work                                     2289           1675         614                   
  Reduced productivity at paid work                          326            566          −240                  
  Absence from unpaid work                                   159            164          −4                    
  Subtotal                                                   2775           2405         370                   (−1363 to 2276)
  *Total costs*                                              4859           5078         −219                  (−2301 to 1825)

Cost-effectiveness analyses {#s3e}
---------------------------

The cost-effectiveness plane with 1000 bootstrapped cost-effect pairs shows a large variation in cost-effectiveness ratios ([figure 2](#BMJOPEN2014007128F2){ref-type="fig"}A). [Figure 2](#BMJOPEN2014007128F2){ref-type="fig"}B shows the probability that the internet-based, nurse-led intervention is cost-effective given a certain threshold value for societal willingness to pay for an extra QALY. Using a threshold value of €20 000 for each QALY gained, there is a 65% probability that the nurse-led, internet-based intervention is cost-effective. This probability increases at higher threshold levels.

![(A) Incremental costs and quality-adjusted life-years (QALYs) for a nurse-led, internet-based vascular risk factor management programme compared with usual care: cost-effectiveness plane for incremental costs and QALYs at 1 year, with CE threshold line (€20 000/QALY). (B) Cost-effectiveness acceptability curve showing the probability that a nurse-led, internet-based vascular risk factor management programme is cost-effective compared with usual care over a range of societal willingness-to-pay values.](bmjopen2014007128f02){#BMJOPEN2014007128F2}

Discussion {#s4}
==========

The results of the clinical study indicated that a nurse-led, internet-based vascular risk factor management programme is effective in lowering the Framingham Heart Risk score in patients with vascular disease by 14% (95% CI −25% to −2%).[@R10] The present economic evaluation showed that this intervention had equal health benefits and lower costs of €219 over 1 year, compared with usual care.

In the past decades, many studies attempted to assess the costs and cost-effectiveness of nurse-led vascular risk management interventions. A randomised controlled trial evaluating the effects of a 1-year nurse-led secondary prevention clinic in primary care for patients with coronary heart disease with a follow-up of 4 years (n=1343), revealed that the costs of the intervention were £136 (€169) with costs per QALY of £1097 (€1360).[@R26] This study was some years ago (1994--1995) and did not use internet, which influences the costs and cost-effectiveness. In another randomised controlled study, evaluating the cost-effectiveness of a web-based primary prevention programme targeted at medical and behavioural risk factors, the incremental cost was €433 and the incremental effectiveness was 0.016 QALYs after 1 year.[@R11] The ICER was €26 910 per QALY. In a retrospective, quasi-experimental design, participants in an internet-based diet and exercise programme were analysed for healthcare costs.[@R27] Among a subgroup of participants with vascular risk factors, healthcare costs during the study year were on average US\$827 lower compared with non-participants with vascular risk factors. These trials suggest that vascular risk reduction by internet-based care might be cost-effective.

The intervention in our study can easily be implemented in regular care for patients who experienced recurrent vascular events as well, either in secondary care or in primary care. An increasing proportion of patients has access to internet at home and nurse practitioners can relatively easily implement internet-based care in their clinical practice. Implementation costs for software are relatively low. However, to be effective and cost-effective, we believe there are some key elements of our internet intervention that need special attention. The internet-based care needs to be tailored to the clinical situation, risk factor levels and personal goals of each individual patient. Personal goal setting is an essential element in a self-management programme. At the start of the study, each patient saw the treating nurse practitioner in person and discussed personal goals and priorities.

A strength of the present study is that the economic evaluation is part of the largest randomised controlled clinical trial on internet-based, nurse-led treatment of patients with vascular disease to date. The drop-out rate was only 5% and data collection was almost complete. Some study limitations need to be considered too. First, we used the Framingham Heart Risk score to estimate the vascular risk.[@R25] Although this vascular risk score is not accurate in estimating the absolute vascular risk in patients with clinical manifest vascular disease, it can be used to evaluate relative differences and changes between groups. Second, as most cost-effectiveness analyses performed alongside clinical trials, our study was not powered to detect a significant difference in costs. Third, we restricted our analysis to actual costs during the intervention period, and disregarded developmental costs and costs for training staff. As these were one-time costs, their impact on the cost of internet-based vascular risk management programme per patient would be very low and is expected to decrease rapidly with time. Another limitation of the clinical trial is that results can be generalised to patients with access to the internet at home and with sufficient computer skills only. Fourth, the burden on patients might be different, but it is unclear if this results in higher or lower burden with the internet-based vascular risk management programme. Portal contacts may replace some real-time contacts, which would reduce patient time investments, such as time spent waiting in the physician's office before an appointment, travel time, etc. Fifth, there was no QALY gain between the intervention and usual care at 1 year intervention. With bootstrapping, we accounted for the uncertainty surrounding the estimation and showed that the intervention had a probability of 65% to be cost-effective compared with usual care (at a €20 000/QALY threshold value).

In conclusion, an internet-based, nurse-led vascular risk programme in addition to usual care to improve vascular risk factors in patients with a recent clinical manifestation of vascular disease does not result in a QALY gain at 1 year, but has a small effect on vascular risk factors and is associated with lower costs.
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